Shen ML, Xu HT, Ju HF, Xian JC, Yang XZ. Sequential telbivudine/lamivudine and hepatitis B immunoglobulin therapy for preventing mother-to-infant transmission of hepatitis B virus.
Shijie Huaren Xiaohua Zazhi 2016;
24:3517-3522. [DOI:
10.11569/wcjd.v24.i23.3517]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
AIM: To assess the value of sequential telbivudine/lamivudine and hepatitis B immunoglobulin (HBIG) therapy in preventing mother-to-infant transmission of hepatitis B virus (HBV).
METHODS: One hundred and seventy-eight enrolled pregnant women were divided into a telbivudine group, a lamivudine group, an HBIG group and a non-preventive group, and they were given the respective drug for preventing mother-to-infant transmission of HBV. At gestational week 12, alanine aminotransferase, total bilirubin, HBsAg, HBeAg, HBV DNA, HBV genotyping, drug resistance related mutations and natural killer cells were detected. Newborns were routinely injected with hepatitis B vaccine, and the HBIG group was additionally given HBIG 200 IU at birth, 3 and 12 wk after birth. Serum levels of HBsAg and HBeAg were detected at birth and 24 wk after birth. The safety of telbivudine and lamivudine was evaluated.
RESULTS: At 12 wk after receiving antiviral drugs, HBV DNA level was significantly reduced in the telbivudine and lamivudine groups compared with the non-preventive group (P < 0.05). No significant difference was observed in gestational age, mean weight or Apgar score of newborns in each group. In addition, no significant difference was observed in alanine aminotransferase, total bilirubin, HBsAg, HBeAg, HBV DNA, HBV genotype, drug resistance related mutations or natural killer cells in each group.
CONCLUSION: HBV DNA level can be significantly inhibited by sequential telbivudine/lamivudine and hepatitis B immunoglobulin therapy in pregnant women with high viral load, which can prevent mother-to-infant transmission of HBV.
Collapse